Ergoteles LLC Verastem, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.33 - $10.44 $204,842 - $6.48 Million	-620,736 Reduced 90.67%	63,875 $25,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $135,611 - $1.65 Million	-147,404 Reduced 17.72%	684,611 $582,000
Q2 2022 Aug 12, 2022	BUY	$1.02 - $1.83 $641,161 - $1.15 Million	628,590 Added 309.0%	832,015 $965,000
Q1 2022 May 13, 2022	BUY	$1.06 - $2.1 $120,338 - $238,406	113,527 Added 126.28%	203,425 $287,000
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $184,290 - $287,673	89,898 New	89,898 $184,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.24B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.